Testing a drug combo for a type of lung cancer with specific gene changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an EGFR inhibitor pill and an intravenous antibody drug conjugate for people with advanced non-small cell lung cancer who have both an EGFR mutation and a HER2 alteration (mutation, amplification, or protein expression). The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer that cannot be removed with surgery.
- Your cancer has a specific EGFR mutation (exon 19 deletion or L858R point mutation).
- Your cancer also has a HER2 alteration (mutation, amplification, or low/high protein expression by IHC).
- You have not had any prior systemic treatments for your cancer (except an EGFR pill within 2 weeks before the trial).
- You are healthy enough to get out of bed and care for yourself (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This study tests a combination of two newer drugs (trastuzumab rezetecan and ivonescimab) for advanced non-small cell lung cancer whose cancer cells have a specific HER2 gene change. The trial includes two groups: people who have already tried one round of treatment, and people newly diagnosed who haven't had treatment yet.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.